Related Experiment Videos
Comparing and Selecting Network Meta-Analysis Models for Cost-Effectiveness Analysis of Anticancer Drugs
Mingye Zhao1,2, Taihang Shao3, Hanqiao Shao1,2
1Department of Pharmacoeconomics, School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, Jiangsu, China.
Objectives:
To systematically evaluate how survival estimates from network meta-analyses (NMA) models affect oncology cost-effectiveness analysis (CEA) results, particularly under different proportional hazards (PH) assumptions and extrapolation strategies.
Methods:
A total of 19 time-to-event NMA models were evaluated in this analysis, encompassing Cox proportional hazards (Cox-PH), fractional polynomial (FP), Royston-Parmar (RP) models, piecewise exponential (PWE), generalized gamma (Gengamma), and parametric survival models (PSM), with 2 extrapolation strategies for non-PH models: a constant-tail hazard ratio (Fixed-HR) and a parametric extrapolation approach (Varying-HR). NMA model performance was assessed via relative error (RE) by comparing CEA outcomes derived from NMA-based survival estimates with those from head-to-head clinical data.
Results:
Fifteen CEA models were conducted. The selection of the NMA model exerted a greater influence on CEA outcomes than traditional model parameters (ie, costs or utilities). RP models appeared to perform best, while PWE, second-order FP, and Gengamma models tended to perform comparatively worse. Fixed-HR extrapolation approaches generally yielded more accurate long-term projections than Varying-HR methods did, particularly under non-PH conditions. Violations of the PH assumption substantially increased uncertainty, especially for non-PH models. Notably, the choice of NMA model led to reversals in cost-effectiveness conclusions in up to one-third of the evaluated CEA cases.
Conclusions:
NMA model choice substantially influences oncology CEA outcomes. Underutilized but well-performing RP models show strong potential for broader application. Fixed-HR extrapolation was preferred in our study. These findings are context specific, and further validation is needed. When PH assumption is violated, the selection of non-PH models requires greater caution. Our findings may offer insights to support future refinements in CEA methodological guidance.
Related Concept Videos
Cancer Survival Analysis
Comparing the Survival Analysis of Two or More Groups
Pharmacokinetic Models: Comparison and Selection Criterion
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Hazard Ratio
For example, in a clinical trial evaluating a...
Analysis of Population Pharmacokinetic Data